Linked Life Data

16977338

Source:http://linkedlifedata.com/resource/pubmed/id/16977338

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2006-9-25
pubmed:abstractText
Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1474-1733
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
715-27
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Cancer despite immunosurveillance: immunoselection and immunosubversion.
pubmed:affiliation
U805 Institut National de la Santé et de la Recherche Médicale, Faculté de Médecine Paris-Sud-Université Paris XI, Institut Gustave-Roussy, 39 rue Camille-Desmoulins, F-94805 Villejuif, France.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't